These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9167009)

  • 1. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
    Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
    Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines.
    Wood DJ; Heath AB
    Biologicals; 1995 Dec; 23(4):301-11. PubMed ID: 8825859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
    Buchheit KH; Daas A
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay.
    Fuchs F; Minor P; Daas A; Milne C
    Pharmeuropa Bio; 2003 Jul; 2003(1):23-50. PubMed ID: 14563307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Pharmacopoeia biological reference preparation for poliomyelitis vaccine (inactivated): collaborative study for the establishment of batch No. 3.
    Martin J; Daas A; Milne C
    Pharmeur Bio Sci Notes; 2016; 2016():135-150. PubMed ID: 28279255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
    Rezapkin G; Dragunsky E; Chumakov K
    Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G; Martin J; Chumakov K
    Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a biological reference preparation for hepatitis A vaccine (inactivated, non-adsorbed).
    Stalder J; Costanzo A; Daas A; Rautmann G; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):15-29. PubMed ID: 20223187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative study for the establishment of the Ph. Eur. BRP for oral poliomyelitis vaccine (OPV) Batch 3 for use in the potency assay.
    Buchheit KH; Daas A; Stalder J
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):67-91. PubMed ID: 12448032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation and standardization of IPV and IPV combination vaccines.
    Baca-Estrada M; Griffiths E
    Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
    Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
    Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic potency of inactivated poliovirus vaccines.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 47():129-33. PubMed ID: 6262143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO Expert Committee on Biological Standardization.
    World Health Organ Tech Rep Ser; 2002; 910():1-104, back cover. PubMed ID: 15497598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
    Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
    Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative study for the establishment of erysipelas ELISA coating antigen. European Biological Reference Preparation batch no. 1.
    Cussler K; Rosskopf-Streicher U; Volkers P; Milne C
    Pharmeuropa Spec Issue Biol; 2001 Aug; 2001(1):75-88. PubMed ID: 11705102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.